Structures and people to govern Dementias Platform UK
Dementias Platform UK (DPUK) is a multi-million pound public-private partnership which launched in 2014. DPUK is directed by Professor John Gallacher (University of Oxford) and is supported by an executive team of ten other representatives from our academic and industry partners.
A steering group of 20 senior scientists, many of whom lead projects across the platform, influence the scientific direction of the project by making recommendations to the executive team.
The director and executive team, in turn, report to an MRC-appointed oversight board twice a year. The board oversee DPUK activity and advise on opportunities or changes for the project. Its members are UK and international experts in the field of dementia.
DPUK is supported by four international advisors, all experts in the field of dementia and neurodegenerative disease.
Funding to enable the platform’s work
Dementias Platform UK has received £53 million from the UK Medical Research Council. Each of our industry partners also makes a contribution – financial or in-kind – to enable the work of the platform.
The amount of additional funding for dementia research that we have attracted can be seen in the table below.
|£ m||Funder and project||Principal Investigator||University||Funding type|
|16||MRC-industry core funding||John Gallacher||Cardiff||Core|
MRC clinical research infrastructure:
Imperial College London,
MRC: Imaging partnership
|1||MRC: Stem Cells partnership||Siddharthan Chandran||Edinburgh||Supported|
Alzheimer's Research UK (ARUK): Imaging
|David Thomas||University College London||Supported|
|2||Stroke Association: Vascular Risk||Joanna Wardlaw||Edinburgh||Supported|
|0.5||Janssen and Alzheimer's Research UK (ARUK): Synaptic Health||James Rowe||Cambridge||Supported|
|60||Innovative Medicines Initiative (IMI): European Prevention of Alzheimer's Dementia Consortium (EPAD)||Craig Ritchie||Edinburgh||Enabled|
|7||MRC National Institute for Health Research (NIHR): Deep and Frequent Phenotyping||Simon Lovestone||Oxford||Enabled|
|3.4||Innovative Medicines Initiative (IMI): Real World Outcomes Across the Alzheimer's Disease Spectrum (ROADS)||John Gallacher||Oxford||Enabled|
|1.1||MRC: UK7T partnership||James Rowe||Cambridge||Enabled|
|7||MRC clinical research infrastructure: UK7T||James Rowe||Cambridge||Enabled|
|0.1||MRC: Korea||Chi-Hun Kim||Oxford||Enabled|
|Research income generated: £83.4 m (157% of core funding)|